HomeHealthcareRare DiseasesHuntington’s Disease Treatment Market

Huntington’s Disease Treatment Market - Strategic Insights and Forecasts (2026-2031)

📥 Download Free Sample💬 Speak to Analyst
$3,950
Single User License
Access Full Insights
Market Size
USD 1.892 billion
by 2031
CAGR
15.15%
2026-2031
Base Year
2025
Forecast Period
2026-2031
Projection
Report OverviewSegmentationTable of ContentsCustomize Report

Table of Contents

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. HUNTINGTON’S DISEASE TREATMENT MARKET BY TYPE

5.1. Introduction

5.2. Medication

5.2.1. Tetrabenazine

5.2.2. Deutetrabenazine

5.2.3. Others

5.3. Therapy

5.3.1. Physical Therapy

5.3.2. Speech Therapy

5.3.3. Disease Modifying Therapy

6. HUNTINGTON’S DISEASE TREATMENT MARKET BY ROUTE OF ADMINISTRATION

6.1. Introduction

6.2. Injectable

6.3. Oral

7. HUNTINGTON’S DISEASE TREATMENT MARKET BY END-USER

7.1. Introduction

7.2. Hospitals

7.3. Specialty Clinics

7.4. Others

8. HUNTINGTON’S DISEASE TREATMENT MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. Germany

8.4.2. France

8.4.3. United Kingdom

8.4.4. Spain

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. India

8.6.3. Japan

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Teva Pharmaceutical Industries Ltd.

10.2. H. Lundbeck A/S

10.3. Bausch Health Companies Inc

10.4. Neurocrine Biosciences, Inc.

10.5. Prilenia Therapeutics

10.6. Novartis AG

10.7. Lupin Limited

10.8. Hikma Pharmaceuticals PLC

10.9. Dr. Reddy's Laboratories Ltd

10.10. Atalanta Therapeutics

10.11. F. Hoffmann-La Roche AG

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

LIST OF FIGURES

LIST OF TABLES

REPORT DETAILS

Report ID:KSI061615578
Published:Jan 2026
Pages:145
Format:PDF, Excel, PPT, Dashboard
📥 Download Sample📞 Speak to Analyst📧 Request Customization

Need Assistance?

Our research team is available to answer your questions.

Contact Us